Tirzepatide vs Retatrutide

Overview

Tirzepatide and Retatrutide represent the evolution of incretin-based obesity treatment. Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist (Mounjaro for diabetes, Zepbound for obesity), while Retatrutide is an investigational triple agonist (GIP/GLP-1/Glucagon) in Phase 3 trials showing potentially even greater weight loss. Both are developed by Eli Lilly.

This comparison examines the current state-of-the-art (tirzepatide) versus the potential next generation (retatrutide) of metabolic peptide therapy.

Key Facts

Aspect	Tirzepatide	Retatrutide
Brand Names	Mounjaro, Zepbound	(Investigational)
Developer	Eli Lilly	Eli Lilly
Receptors	GIP + GLP-1 (dual)	GIP + GLP-1 + Glucagon (triple)
FDA Status	Approved	Phase 3
Max Weight Loss	~22.5% (SURMOUNT-1)	~24.2% (Phase 2)

Mechanism Comparison

Aspect	Tirzepatide	Retatrutide
GLP-1 Agonism	Yes	Yes
GIP Agonism	Yes	Yes
Glucagon Agonism	No	Yes
Total Receptors	2	3
Novel Mechanism	Dual agonist	Triple agonist

Tirzepatide Mechanism

1. GLP-1 Receptor Activation

   • Appetite suppression
   • Delayed gastric emptying
   • Insulin secretion (glucose-dependent)
   • Proven weight loss mechanism

2. GIP Receptor Activation

   • Enhanced insulin response
   • Lipid metabolism effects
   • Central appetite effects
   • Synergistic with GLP-1

3. Combined Effects

   • Superior to GLP-1 alone
   • Better glycemic control
   • Greater weight loss than semaglutide

Retatrutide Mechanism

1. GLP-1 + GIP (Same as tirzepatide)

   • Appetite suppression
   • Insulin enhancement
   • Metabolic improvements

2. Glucagon Receptor Activation (Novel)

   • Increased energy expenditure
   • Enhanced fat oxidation
   • Hepatic effects
   • Thermogenesis

3. Triple Synergy

   • Three complementary pathways
   • Potentially superior efficacy
   • Novel mechanism combination

Clinical Trial Results

Tirzepatide Weight Loss Data

Trial	Dose	Weight Loss	Duration
SURMOUNT-1	15mg	22.5%	72 weeks
SURMOUNT-1	10mg	21.4%	72 weeks
SURMOUNT-1	5mg	16.0%	72 weeks
SURMOUNT-2 (T2D)	15mg	15.7%	72 weeks

Retatrutide Weight Loss Data (Phase 2)

Trial	Dose	Weight Loss	Duration
Phase 2	12mg	24.2%	48 weeks
Phase 2	8mg	22.8%	48 weeks
Phase 2	4mg	17.5%	48 weeks

Note: Phase 2 retatrutide data at 48 weeks vs tirzepatide Phase 3 at 72 weeks. Direct comparison is approximate.

Efficacy Comparison

Metric	Tirzepatide	Retatrutide
Maximum Weight Loss	~22.5%	~24.2% (Phase 2)
Data Maturity	Phase 3 confirmed	Phase 2 only
Comparison to Sema	Superior	Appears superior
Metabolic Effects	Excellent	Potentially excellent

Potential Retatrutide Advantages

Factor	Mechanism
Greater weight loss	Glucagon adds thermogenesis
Fat reduction	Glucagon increases fat oxidation
Energy expenditure	Triple agonist effect
Liver effects	Glucagon hepatic benefits

Side Effect Profiles

Tirzepatide (Established)

Effect	Frequency	Notes
Nausea	Common (20-30%)	Decreases over time
Diarrhea	Common	Dose-related
Vomiting	Common	Initial weeks
Constipation	Common	GI effects
Generally manageable	Yes	Titration helps

Retatrutide (Phase 2 Data)

Effect	Frequency	Notes
GI effects	Similar to tirzepatide	Expected class effects
Nausea	Common	Dose-dependent
Glucagon effects	Heart rate increase	Monitoring needed
Safety profile	Acceptable in Phase 2	Phase 3 will clarify

Glucagon Considerations

Concern	Status
Heart rate	Modest increase observed
Blood glucose	Balanced by GLP-1/GIP
Muscle preservation	Potential benefit
Long-term effects	Phase 3 will evaluate

Regulatory Status

Aspect	Tirzepatide	Retatrutide
FDA (Obesity)	Approved (Zepbound)	Phase 3
FDA (Diabetes)	Approved (Mounjaro)	Not filed
EMA	Approved	Not filed
Availability	Widely available	Not available
Timeline	Now	2025-2026 potential

Administration

Aspect	Tirzepatide	Retatrutide
Route	Subcutaneous	Subcutaneous
Auto-injector	Available	Expected

Cost Considerations

Factor	Tirzepatide	Retatrutide
Current Price	~$1,000-1,200/month (US)	Not available
Insurance Coverage	Variable	TBD
Expected Pricing	Established	Similar or higher
Global Access	Expanding	Future

Who Might Choose Each?

Tirzepatide (Now)

Candidate	Rationale
Needs treatment now	FDA-approved, available
Good response expected	Dual agonist effective
T2D + obesity	Approved for both
Stable option	Known safety/efficacy

Retatrutide (Future)

Candidate	Rationale
Wants maximum efficacy	Potentially superior
Tolerates glucagon effects	HR increase acceptable
Failed other options	Novel mechanism
Trial access	Currently enrolling

Development Timeline

Tirzepatide History

Date	Milestone
2022	FDA approved (diabetes)
2023	FDA approved (obesity)
2024	Widespread availability
Ongoing	Additional indications

Retatrutide Timeline

Date	Milestone
2023	Phase 2 results published
2024	Phase 3 trials ongoing
2025-2026	Potential FDA filing
2026-2027	Potential approval

NASH/MASH Considerations

Factor	Tirzepatide	Retatrutide
Liver Effects	Being studied	Glucagon adds benefit
NASH Trials	SYNERGY-NASH ongoing	Being evaluated
Liver Fat Reduction	Significant	Potentially superior

Summary

Factor	Tirzepatide	Retatrutide
Agonist Type	Dual (GIP/GLP-1)	Triple (GIP/GLP-1/Glucagon)
FDA Status	Approved	Phase 3
Max Weight Loss	22.5%	24.2% (Phase 2)
Availability	Now	2026+
Data Maturity	Phase 3 confirmed	Phase 2 only
Novel Mechanism	Yes	Yes (glucagon adds)
Side Effects	GI primarily	GI + HR increase

Key Takeaways

1. Tirzepatide is available now: FDA-approved for both diabetes and obesity
2. Retatrutide adds glucagon: Triple agonist may offer additional benefits
3. Phase 2 shows promise: Retatrutide 24.2% vs tirzepatide 22.5% weight loss
4. Phase 3 needed: Retatrutide efficacy/safety must be confirmed
5. Similar developer: Both from Eli Lilly
6. Timeline matters: Tirzepatide available; retatrutide 2026+ optimistically
7. Glucagon effects: Heart rate increase is monitoring consideration
8. Evolution continues: Each generation potentially more effective

---

This comparison is for educational purposes only. Tirzepatide is FDA-approved. Retatrutide is investigational. Discuss treatment options with a healthcare provider.